Neuberger Berman Group
DYN icon

Neuberger Berman Group’s Dyne Therapeutics DYN Stock Holding History

Neuberger Berman Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-165,482
Closed -$3.24M – 2185
2025
Q4 		$3.24M Sell
165,482
-155,944
-49% -$2.95M ﹤0.01% 1058
2025
Q3 		$4.07M Buy
321,426
+121,160
+60% +$1.38M ﹤0.01% 1008
2025
Q2 		$1.91M Buy
+200,266
New +$2.2M ﹤0.01% 1174
2025
Q1 		– Sell
-152,306
Closed -$3.59M – 1994
2024
Q4 		$3.59M Buy
152,306
+15,240
+11% +$451K ﹤0.01% 1013
2024
Q3 		$4.92M Buy
+137,066
New +$5.46M ﹤0.01% 945

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Neuberger Berman Group's DYN Position: Q1 2026 in Review

Neuberger Berman Group sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 165,482 shares — an estimated $3.24M sold.

Neuberger Berman Group first reported a position in DYN in Q3 2024 and held it in 5 quarters. The position peaked at $4.92M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Neuberger Berman Group reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Neuberger Berman Group sold 165,482 Dyne Therapeutics shares in Q1 2026, an estimated $3.24M.
  • Neuberger Berman Group first reported a position in Dyne Therapeutics in Q3 2024 and held it in 5 quarters.
  • Neuberger Berman Group's Dyne Therapeutics position peaked at $4.92M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.